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Summary 
The term “neurogenic inflammation” has been adopted to describe the local release of inflammatory 
mediators from neurons such as substance P and calcitonin gene related peptide. Once released, 
these neuropeptides cause histamine release from adjacent mast cells. In turn, histamine evokes the 
substance P and calcitonin gene related peptide release, thus a bidirectional link between histamine 
and neuropeptides in neurogenic inflammation is established. The aim of this review is to 
summarize the most recent findings on the role of histamine in neurogenic inflammation with 
particular regards to nociceptive pain as well as neurogenic inflammation in the skin, in the airways 
and in the bladder. 
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Introduction 
The term “neurogenic inflammation” describes the local release of inflammatory mediators from 
afferent neurons such as substance P (SP) and calcitonin gene related peptide (CGRP). Since the 
first evidences of a neurogenic vasodilatation in response to noxious stimuli in the skin of humans 
and other mammals (Schmelz M et al., 2001), nowadays it is recognised that neurogenic 
inflammation occurs also in visceral organs. The inflammatory response evoked by the activation of 
the sensory nerve fibres, including local vasodilatation, plasma extravasation, leukocyte and platelet 
adhesion, and mast cell degranulation, is brought about by neuropeptides released from peripheral 
endings of sensory neurons upon stimulation of the primary sensory terminals. Both SP in neurons 
and histamine in mast cells have a dual mediator role in neurogenic inflammation (Figure 1). In 
fact, as described by Foreman and Jordan (1984), injury causes activation of sensory nerve endings 
either directly or through the release of histamine from adjacent mast cells. The action potential 
generated travels orthodromically to the dorsal horn of the spinal cord, and spreads to other 
branches of the same neurons which will then release SP from their terminals or varicosities. The 
released SP, besides contributing by itself to local vasodilatation, causes histamine release from 
adjacent mast cells which produce flare and further activates other sensory nerve endings (Foreman 
JC et al., 1984).  
Neutrophils, whose responsiveness to SP has been repeatedly demonstrated, contribute to the 
inflammatory soup following neurogenic inflammation. In fact, neutrophils express the SP receptors 
NK1, NK2 and NK3, and their challenge with SP induces COX-2 expression and PGE2 release in the 
nanomolar range (Gallicchio M et al., 2008; Gallicchio M et al., 2009). Furthermore, SP at 
micromolar concentrations primes neutrophils, thus enhancing O2- production evoked by platelet-
activating factor (PAF) (Brunelleschi S et al., 1991). In the picomolar range SP still induces 
netrophil adhesion to human umbilical vein endothelial cells (Dianzani C et al., 2003). 
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Together with histamine, other mast cell-derived mediators (such as, serotonin, renin, adenosine, 
heparin, tryptase, chymase, elastase, carboxypeptidase A and B, cathepsin, b-galactosidase, b-
glucoronidase, matrix metalloproteinase, chemotatactic factors for eosinophils and neutrophils, 
platelet derived factor, prostaglandin D2, leukotriene B4, C4 and D4, tromboxane A2 and B2, nitric 
oxide, TNF- and other cytokines, neuropeptides) contribute to the functional picture of neurogenic 
inflammation (Tore F et al., 2009). Experimental evidences support their role demonstrating their 
neuronal receptors. 
Histamine and neurogenic inflammation: experimental evidences 
The evidences for a neurogenic mechanism in the involvement of SP in the flare response stems 
from data showing that local anaesthetic injection into the human skin reduced the spread of the 
flare response although without affecting the development of the wheal response (Foreman JC et 
al., 1983). Otherwise the role of histamine has been investigated mostly by specific receptor-
oriented approaches. The effects of SP on flare response in human skin are mimicked only by the 
neuropeptide fragments able to degranulate rat mast cells in vitro (Fewtrell CM et al., 1982). The H1 
histamine antagonist chlorpheniramine (20 mg i.v.) has been reported to prevent the spread of the 
flare response to SP in the human skin (Foreman JC et al., 1983). These first observations of the 
role of histamine in the neurogenic inflammation have been further elucidated thanks to 
immunoistochemical studies demonstrating the proximity of mast cells and nerve fibres containing 
neuropeptides, with first studies in dura mater and gut, while larger body of evidence is available 
for the skin (Nakanishi M et al., 2008). Moreover, Janiszewski et al. (1990) have demonstrated in a 
co-colture system that the activation of peritoneal mast cells induce depolarization and decrease 
membrane resistance in sympathetic neurons (Janiszewski J et al., 1990). A bidirectional 
communication between nerves and mast cells has been supported by the presence of receptors for 
many neuropeptides (such as vasoactive intestinal peptide, neuropeptide Y, SP, CGRP, 
propiomelanocortin, galanin, neuromedin U, pituary adenilate cyclise-activating polypeptide, 
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neurotenisn and corticotrophin-releasing factor) on mast cells surface. Thus these mediators can 
exert both paracrine and autocrine effects on mast cells (Figure 1). Similarly, also histamine exerts 
autocrine effects on mast cells as they express all the histamine receptors H1-4 (Tore F et al., 2009).  
Notably, the interactions between mast cells and adjacent nerves is also accomplished by adhesion 
molecules such as N-cadherin or cell adhesion molecule (CADM)-1, a calcium-dependent adhesion 
protein that can be cleave by the metalloproteinase MT5-MMP of the peptidergic receptors in the 
dorsal root ganglion (Guillot X et al., 2012; Nakanishi M et al., 2008).  
Histamine, neurogenic inflammation and nociceptive pain 
While the contribution of neurogenic inflammation to nociception has been previously elucidated 
(Julius D et al., 2001), more recently detailed analysis of the role of histamine receptors has been 
investigated. 
Mechanoinsensitive C-fibres are known to be activated by histamine and to be responsible for the 
neuropetide release, for example in the skin inducing the axon reflex flare (Groetzner P et al., 
2010). Histamine-immunoreactive nerve fibres have been found in the superficial laminae of the 
dorsal horn, an important site for nociceptive transmission. The mRNA of histamine H1 receptor 
genes has been detected in many SP and CGRP immunoreactive neurons following the peripheral 
nerve injuries (Kashiba H et al., 1999), and histamine has been reported to mediate the release of SP 
and glutamate in inflammatory conditions (Riedel W et al., 2001). Moreover, a bidirectional 
relationship between CGRP and histamine can be proposed  according to the data showing that: 
CGRP induces histamine release from mast cells and potentiates histamine effects in the rat 
(Mobarakeh JI et al., 2006); intraperitoneally injection of histamine induces CGRP release into the 
cerebrospinal fluid (Bileviciute I et al., 1994); histamine administrated to the nasal mucosa causes 
CGRP release from peripheral terminals of trigeminal ganglion in the guinea pig (Tani E et al., 
1990). Further support of a cooperation between histamine and CGRP is afforded by the 
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observation of a colocalization of both the histamine H3 receptor and CGRP on A  fibres; both 
mediators contributing to an high threshold mechanical nociceptive effect (Cannon KE et al., 2007).  
More recently, it has been demonstrated that both the H1 receptor antagonist pyrilamine and the H2 
receptor antagonist ranitidine produce a dose-dependent antinociceptive response in the formalin 
test, and that a histamine intrathecally-induced hyperalgesia has been blunted by the GCRP 
antagonist CGRP 8-37 (Mobarakeh JI et al., 2011).  
Studies with histamine H1 receptor knockout mice have demonstrated that both the receptor and its 
natural ligand are necessary to facilitating pain transmission at both peripheral and central levels 
(Mobarakeh JI et al., 2002; Mobarakeh JI et al., 2000). By using histidine decarboxylase (HDC) 
gene knockout mice it has been shown that the NK1 receptors in the spinal cord mediate the 
histamine-induced hyperalgesic responses (Yoshida A et al., 2005). Several in vivo studies have 
evaluated the antinociceptive efficacy of antihistamines. The administration of H1 and H2 receptor 
antagonists, chlorpheniramine and cimetidine respectively, was found to inhibit the development of 
both thermal and mechanical hyperalgesia, although chlorpheniramine was more potent (Zuo Y et 
al., 2003). Even the most recently discovered histamine receptors, the H3 and H4 receptors, have 
been shown to be involved in mediating nociception. The pre-treatment with H3/H4 receptors dual 
antagonist thioperamide attenuated c48/80-induced thermal pain 30 min after challenge without 
causing analgesia (Chatterjea D et al., 2012). Moreover, it was reported that H3 receptor 
antagonists, such as GSK-189254 and ABT-239, are effective in reducing allodynia and 
hyperalgesia in models of neuropathic, and inflammatory pain (Hsieh GC et al., 2010b; Medhurst 
AD et al., 2007; Medhurst SJ et al., 2008).  
Focusing on H4 receptors, both the experimental antagonists JNJ7777120 (10 and 30 mg kg-1, s.c.) 
and VUF6002 (10 mg kg-1, s.c.) significantly reduced the paw oedema and hyperalgesia provoked 
by subplantar injection of carrageenan (Coruzzi G et al., 2007). According to these data, 
JNJ7777120 reversed hyperalgesia in both acute and chronic pain models (Hsieh GC et al., 2010a). 
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Notably, the same study has reported no effect for H1 receptor antagonist diphenhydramine, H2 
receptor antagonists ranitidine, or H3 receptor antagonist ABT-239, thus suggesting a dominant role 
of the H4 receptors in animal models of inflammatory and neuropathic pain. 
All together, these data from animal models may be regarded as indicative of a potential efficacy of 
antihistamines in clinical setting. However, clinical evidence is still lacking and previously trials 
were negative (Raffa RB, 2001). 
Histamine and neurogenic inflammation in the skin 
The involvement of histamine in cutaneous neurogenic inflammation stems from the observation 
that this amine triggers the so called “triple response”. Nowadays, local erythema results from the 
axon reflex and antidromic sensory nerve stimulation-induced release of different vasoactive 
mediators, not only histamine, but also SP, histamine, purines and CGRP. Itch is mediated via 
dedicated afferent nonmyelinated C-type nerve fibres different from the polymodal C-fibres  being 
unresponsive to mechanical stimulation. The so called ‘pruriceptors’ are differentiated in histamine-
sensitive and histamine-independent itch-specific C-fibres. In particular, histamine–sensitive C-
fibres, about the 5% of afferent C-fibres in human cutaneous nerves, are characterized by slow 
conduction velocities and extensive terminal branching (Raap U et al., 2011; Shim WS et al., 2008). 
When activated by histamine, they transmit electrical signals to the superficial layer of the dorsal 
horn of the spinal cord. These signals then ascend to the thalamus through contralateral 
spinothalamic tracts and are eventually conducted to the somatosensory and cingulated cortex 
(Figure 2). All the histamine receptors are involved in mediating histamine signal on neurons, but 
with a different functional weight. The failure of cimetidine to suppress histamine-induced itch in 
BalbC mice (Bell JK et al., 2004) do not support an involvement of H2 receptor in itch. The H1 
receptor is the most extensively studied. Indeed, H1 receptor blockers have an established and 
valuated place in the treatment of itching of allergic and non-allergic origin (Skidgel RA et al., 
2011). 
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Intriguing data on the H3 receptor seem to contradict the aforementioned histamine-induced itch 
pathway (Summey BT et al., 2005), as antagonists such as thioperamide or AQ0145 were found to 
increase significantly the incidence of scratching behaviour in mice (Sugimoto Y et al., 2004). 
Histamine H3 receptor antagonists might block the modulatory role afforded by the presinaptic H3 
receptor, thus favouring the release of neuropetides from sensory endings (Cannon KE et al., 2007). 
More recently, data obtained with clobenoprit, an H3 receptor antagonists and H4 receptor agonist, 
suggested that H4 receptor also is involved in itch. Clobenoprit caused scratching responses in the 
mouse that were attenuated by pretreating animals with the H4 receptor antagonist, JNJ7777120 
(Dunford PJ et al., 2007). Moreover, it has been reported that H4 receptor agonists are able to 
induce itch through a direct action on peripheral nerves (Bell JK et al., 2004), and that the H4 
antagonist inhibit SP-induced itch, which has been reported to be resistant to H1 receptor 
antagonists (Yamaura K et al., 2009). More recently, Suwa et al. (2011) have demonstrated that 
JNJ7777120 (10 and 30 mg kg-1 die), and not the histamine H1 receptor antagonist fexofenadine (30 
mg kg-1 die), reduces the scratching behaviour and ameliorates the skin lesions induced by repeated 
challenge with 2,4,6-trinitrochlorobenzene in HR-1 mice, in a dose-dependent manner (Suwa E et 
al., 2011). 
Interestingly, in the mice blocking both the H1 receptors and the H4 receptors, by a dual antagonist 
or a combination therapy gave the maximum response, almost completely abolish the itch response 
(Dunford PJ et al., 2007).  
Besides, other published data indicate that H1 receptors and H4 receptors share a similar pathway in 
the neuron excitation by increasing intracellular Ca2+ levels (Shim WS et al., 2008). Histamine 
elevates calcium levels through H1 receptor in rat cultured sensory neurons, and this effect is 
blocked by the PLC inhibitor U73122 (Nicolson TA et al., 2002).  
Moreover, in mouse sensory neurons stimulated by capsaicin, histamine induces inward currents 
and calcium influx in a TRPV1-dependent manner, as demonstrated by the blocking effect of 
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TRPV1 antagonists; in keeping with these results histamine-induced scratching is significantly 
lower in TRPV1-deficient mice (Kajihara Y et al., 2010; Shim WS et al., 2007). 
All these evidences explain at least in part the antipruritic effects of both mirtazapine and doxepin, 
two antidepressant that share also additional antihistaminic effects (Raap U et al., 2011). Moreover, 
the well recognised risk-benefit profile of H1 antihistamines, especially the non-sedative second 
generation ones, lead the European Academy of Allergy and Clinical Immunology to recommend in 
its guidelines an updosing of nonsedating antihistamines up to four-fold in patients with chronic 
urticaria. Clinical studies on H4 receptor antagonists are currently ongoing (Engelhardt H et al., 
2009). 
Histamine and neurogenic inflammation in the airways 
Misery (2008) approached the intriguing parallelism between itch/scratching and cough starting 
from a common pathophysiology that involves the C fibres, the mast cells, histamine, SP and other 
tachykinins. Indeed, the close proximity between mast cells and the nerve endings in the lung 
suggests a similar neuro-immuno crosstalk (Misery L, 2008) as found in the skin. Sensory nerve 
endings release neuropeptides such as SP and CGRP, which induce mast cell activation and 
degranulation. The antidromic release of neuropeptides from nociceptors in the airways causes 
vasodilatation and oedema associated with nasal obstruction in the upper airways, and 
broncocostriction in the lower airways, as well as plasma protein exudation, mucus secretion and 
inflammatory cell recruitment. As a proof of neurogenic inflammation in the airways, local 
anaesthesia with lidocaine improved airway hyperreactivity and reduced capsaicin-induced cough 
(Muraki M et al., 2008). 
A first evidence of the relationship between SP and histamine in the airways came in 1994, when 
Heaney et al. (1994) demonstrated the ability of SP to stimulate human mast cells obtained from 
bronchoalveolar lavage (Heaney LG et al., 1994). More recently, sputum SP and mast cell tryptase 
concentrations were remarkably increased in patients with chronic cough, and evenly increased in 
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those with cough due to gastro-oesophageal reflux disease (GERD). These latter data suggest that 
GERD-induced cough may be related to a cough reflex hypersensitivity caused by neurogenic 
airway inflammation (Qiu Z et al., 2011), and are in keeping with the results obtained by Birring et 
al. (2004), who measured an increased histamine content in the sputum of patients with idiopathic 
chronic cough and cough variant asthma/eosinophilic bronchitis in comparison with normal subjects 
(Birring SS et al., 2004). Rat lung mast cells have been found to release histamine in response to 
high doses of SP in vitro; moreover, it has been shown that the NK1 receptor-mediated mast cell 
activation partly affords for airway plasma leakagein F344-, but not in BDE-rats, exposed to SP and 
capsaicin. The airway responsiveness to tachykinins discriminates these two inbred strains. 
Actually, only the  F344 presents NK1 receptors mast cells that display a proreleasing effect 
(Pauwels RA et al., 1995). More recently, it has been reported that CP-99,994 (5 mg kg-1 i.v.), a 
NK1 receptor antagonist, abolished the microvascular leakage elicited in the rat airways by a single 
inhalation of toluene-2,4-diisocyanate. On the contrary, ketotifen (1 mg kg-1 i.v.), provided with H1 
antagonism and mast cell-stabilizing properties, did not exert any effect in this model (Sakamoto T 
et al., 2012). In a model of microvascular leakage hypersensitivity induced in the airways of guinea-
pigs aerosolised with histamine it has been demonstrated that, while NKB and the NK3 receptor 
agonist senktide, enhanced airway hypersensitivity to histamine. In the same model, both the 
tachykinin NK3 receptor antagonists osanetant and the NK1 receptor antagonist nolpitantium were 
able to abolish the histamine-induced microvascular leakage. NK2 ligands were uneffective (Daoui 
S et al., 2001). Moreover, it has been reported that toluene-2,4-diisocyanate exposure causes an 
increase in histamine content, HDC activity and gene expression in the nasal mucosa of sensitized 
rats (Kitamura Y et al., 2004). Olopatadine hydrochloride, an H1 receptor antagonist, besides 
inhibiting the capsaicin-induced sneezing response, has been found to inhibit antigen-induced 
sneeze and nasal rubbing responses in both wild-type and H1 receptor-deficient mice, although at 
very high doses (Tamura T et al., 2008), thus suggesting a H1 receptor independent effect. Indeed, 
these data, together with the failure of cetirizine to inhibit completely these responses in H1 
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receptor-deficient mice (Kayasuga R et al., 2002; Sugimoto Y et al., 2004), could lead to 
hypothesise the involvement of other receptors in these responses. 
Histamine and neurogenic inflammation in the bladder 
Interstitial cystitis (IC), or painful bladder syndrome (PBS), numbers among its causes neurogenic 
inflammation; in fact, an increased density of nerve fibres has been reported (Peeker R et al., 2000). 
Evidences from both rodent and humans highlight an important role for mast cells. Activated mast 
cells have been associated to the rodent neurogenic cystitis induced by the Bartha strain of 
pseudorabies virus (PRV) (Chen MC et al., 2006; Jasmin L et al., 2000). Moreover, clinical studies 
have demonstrated elevated mast cell number in the lamina propria of IC bladder biopsies (Leiby 
BE et al., 2007) and an increased urinary histamine metabolites (el-Mansoury M et al., 1994). 
Although the central role of mast cells in PBS/IC is still unclear, in vivo model of IC pathogenesis 
suggested a positive feedback loop with SP containing peripheral nerves and mast cells: the 
activation of the bladder-associated circuits in the CNS initiates SP release by peripheral nerves in 
the bladder leading SP-mediated mast cell activation. Consequently, mast cell degranulation induces 
bladder inflammation by acting on urothelium. Histamine contribute to IC/PBS, is not only in 
evoking an inflammatory response, but seems also to be related to pelvic pain. In fact, histamine 
and histamine receptors as mediators in pain responses have been described in both animal models 
and humans (Mobarakeh JI et al., 2006; Thilagarajah R et al., 2001). Although the specific cell type 
among mast cells, basophils, neutrophils, dendritic cells and histaminergic neurons regulating 
histamine-mediated pain is unknown, it has been demonstrated, by using a model of PRV-induced 
pelvic pain in mast cell deficient KitW-sh/KitW-sh mice, that mast cells are required for histamine-
mediated pelvic pain (Rudick 2008). However, the same authors demonstrated that KitW-sh/KitW-sh 
mice reconstituted with HDC-/-bone marrow exhibited diminished pain, thus suggesting that non-
mast cell sources of histamine may also contribute to pain. Moreover, Rudick CN et al. (2008) 
demonstrated that PRV induced pelvic pain is independent from TNF-dependent pathology and 
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instead is mediated by mast cell histamine, which then induces pain via histamine receptors H1 and 
H2 (Rudick CN et al., 2008). Thus, it has been suggested that antagonists of histamine H1 and H2 
receptors are candidates for clinical trials in the treatment of chronic pain conditions, such as IC-
related pelvic pain. Indeed, pilot clinical studies suggest that antihistamine therapy could be 
effective on IC-related pelvic pain. In particular, a symptomatic improvement has been reported in 
30% of patients treated with the H1 receptor antagonist hydroxyzine hydrochloride from 25 mg/die 
at night to 50 mg at night + 25 mg in the morning over a 2-week period (Theoharides TC et al., 
1997). Although these positive results suggest a therapeutic role of histamine H1 receptor antagonist 
in the treatment of IC/PBS, further studies with newer generation histamine H1 receptor antagonists, 
with a lesser sedation component, have to be conducted. Moreover, the histamine H2 receptor 
antagonist cimetidine produced significant improvement in pain and nocturia in a limited trial of 
PBS patients (Thilagarajah R et al., 2001). It has to be stressed that approximately 90% of patients 
with PBS/IC are women, thus suggesting that the process involving mast cells may be hormonally 
influenced. In fact, oestrogen receptors (ERs) are expressed on human mast cells and can mediate 
their degranulation, while the ER antagonist tamoxifen inhibits this fenomenon (Rudick CN et al., 
2012). 
 All together these findings suggest that reproductive hormones may modulate IC symptoms at the 
mast cell levels. This hypothesis has been recently tested by Rudick CN et al. (2012) who assessed 
the basis of gender specific pelvic pain in the murine model of neurogenic cystitis PRV-induced. 
The data obtained suggest that pelvic pain in mice with murine neurogenic cystitis is mediated by 
gender specific responsiveness to mast cells, in contrast pelvic pain severity resulted to be 
modulated by genetic factors (Rudick CN et al., 2012). 
Conclusion 
In conclusion, experimental data here included widely show the complex physiopatological 
mechanism(s) known as neurogenic inflammation and the key role played by histamine (Table 1). 
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Neurogenic inflammation is involved in several processes of animal and human physiopathology: 
this review, with no ambition to be completely exhaustive, has anyway outlined the most up-to-date 
and widest fields of investigation. A comprehensive evaluation of the histamine role in neurogenic 
inflammation, as discussed here, highlights how the many experimental evidences have not yet 
reached a full clinical transferability and not yet support new pharmacotherapeutic approaches. 
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Table 1. Effect of selective histamine receptor antagonism in neurogenic inflammation 
Effect Histamine receptor subtype 
H1R H2R H3R H4R 
Pain     
Hyperalgesia*     
Allodynia ? ?  ? 
Itch     
Sneezing response ** ? ? ? 
*The differential involvement of histamine receptor subtypes has been demonstrated by different 
experimental models  
**only at high doses 
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Legends 
Figure 1. The dual mediator role of mast cells: bidirectional interaction nerves-mast cells. 
Neuropeptide released from sensory nerve endings stimulate adjacent mast cells in a receptor 
dependent manner. Mediators released from mast cells act in both a paracrine and autocrine fashion. 
CGRP= calcitonin gene related peptide; SP= substance P; VIP= vasoactive intestinal peptide 
Figure 2. The itch system. Histamine released from mast cells after a local stimulus activates 
histamine-sensitive pruriceptors, thus generating an actions potential which orthodromically travels, 
through to the dorsal horn of the spinal cord and the thalamus, to the cortex (blue line). The 
following antidromic stimulation induces the release of different mediators from sensory endings, 
substance P (SP) and calcitonin gene related peptide (CGRP). SP and CGRP released causes further 
mast cells degranulation resulting in vasodilatation (flare) and the recruitment of other pruriceptors. 
 
 
